Mimedx (MDXG) Capital Expenditures Growth (3y) (2014 - 2025)
Mimedx (MDXG) Capital Expenditures Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 16.27% |
| 10 | Mimedx | 647.97 Mn | 488.19 Mn | 41.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.68% |
| Sep 30, 2025 | -18.06% |
| Jun 30, 2025 | -22.19% |
| Mar 31, 2025 | 47.28% |
| Dec 31, 2024 | -6.81% |
| Sep 30, 2024 | -32.13% |
| Jun 30, 2024 | -36.24% |
| Mar 31, 2024 | -16.16% |
| Dec 31, 2023 | -2.67% |
| Sep 30, 2023 | -50.80% |
| Jun 30, 2023 | 31.49% |
| Dec 31, 2022 | -1.46% |
| Sep 30, 2022 | 30.79% |
| Jun 30, 2022 | 14.83% |
| Mar 31, 2022 | -43.32% |
| Dec 31, 2021 | -43.78% |
| Sep 30, 2021 | -35.61% |
| Jun 30, 2021 | -45.28% |
| Mar 31, 2021 | -14.16% |
| Dec 31, 2020 | 24.08% |